Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaueschingen – page 20

591 clinical trials in Donaueschingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaueschingen at a glance
591
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

591 trials in Donaueschingen

Open in trial search

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Gastrectomy

Recruiting

Study on the Effects of Amylase, Protease, and Rizolipase for Patients After Gastrectomy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amylase
  • Sponsor:University of Leipzig

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effectiveness of L19IL2 and L19TNF Injections with Surgery for Patients with Stage IIIB/C Melanoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Universitair Medisch Centrum Utrecht

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Universitaetsmedizin Goettingen

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Study on Dapagliflozin and Lifestyle Changes for Patients with Early Chronic Kidney Disease and Prediabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Synovial sarcoma+2

Recruiting

Study of Personalized Peptide Vaccine with PERVI-FUS, PERVI-NEO, and 11902A for Children and Young Adults with Metastatic Fusion-Driven Sarcomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Pervi-Fus
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaueschingen

What the registry says about research in the country

01 Pulmonary Research

Groundbreaking clinical trials focusing on pulmonary arterial hypertension (PAH) are exploring innovative treatment approaches. The research aims to evaluate new therapeutic interventions for patients dealing with this challenging cardiovascular condition.

  • Treatment Efficacy Assessment
  • Safety Profile Evaluation
  • Clinical Progression Monitoring

These studies are designed to track and assess clinical outcomes in PAH patients, with particular attention to preventing disease progression and improving patient well-being.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.